ORADUR® Abuse-deterrent Technology

ORADUR technology is focused on addressing two interrelated challenges: extending the therapeutic duration of conventional short-acting drugs and protecting the required high drug loads from tampering and improper extraction.

Proprietary ORADUR gel matrices can accommodate high concentrations of active compounds, consistent with the goal of once- and twice-daily dosing, and are also designed to provide built-in resistance to improper release or extraction of the active agents.

ORADUR technology is designed with the following objectives in mind:

  • High drug loads, supporting extended dosing intervals
  • Built-in tamper resistance
  • Near-zero-order release kinetics
  • Standard manufacturing and encapsulation process, for low-cost scalability

ORADUR-based products in development include opioid analgesics targeted at chronic pain and methylphenidate capsules proposed to treat attention-deficit hyperactivity disorder (ADHD). The effective dosing intervals and ability of these investigational products to resist common forms of tampering, such as crushing and dissolving in liquids, are under evaluation.

Both opioid analgesics and methylphenidate expose patients to risks of addiction, abuse, and misuse even when abuse-deterrent properties are present. ORADUR-based products are investigational and have not been approved by the FDA for marketing in the U.S. for any indication.

Learn more about ORADUR-based pipeline products: